Compare RMBI & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | PYXS |
|---|---|---|
| Founded | 1887 | 2018 |
| Country | United States | United States |
| Employees | N/A | 56 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.0M | 166.6M |
| IPO Year | 2019 | 2021 |
| Metric | RMBI | PYXS |
|---|---|---|
| Price | $15.16 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 50.5K | ★ 1.0M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 27.17 | 3.03 |
| EPS | ★ 0.28 | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | $54.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.77 | $0.97 |
| 52 Week High | $16.59 | $5.55 |
| Indicator | RMBI | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 63.75 |
| Support Level | $13.10 | $1.37 |
| Resistance Level | $16.04 | $2.92 |
| Average True Range (ATR) | 0.56 | 0.32 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 33.49 | 55.75 |
Richmond Mutual Bancorp Inc is a bank holding company. Along with its subsidiary, it is mainly engaged in attracting deposits from the general public, as well as brokered deposits, and investing those funds in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one- to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. It also obtains funds by utilizing Federal Home Loan Bank (FHLB) advances. These funds are generally invested in investment securities, including mortgage-backed and mortgage-related securities and agency and municipal bonds. The Group's primary market area includes Wayne and Shelby counties in Indiana and Shelby, Miami, and Franklin counties in Ohio.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.